<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669601</url>
  </required_header>
  <id_info>
    <org_study_id>ATRiUM</org_study_id>
    <nct_id>NCT03669601</nct_id>
  </id_info>
  <brief_title>AZD6738 &amp; Gemcitabine as Combination Therapy</brief_title>
  <acronym>ATRiUM</acronym>
  <official_title>A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of Combined Therapy With ATR Inhibitor AZD6738 and Gemcitabine, Using a Model Based Design.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CCTU- Cancer Theme</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose escalation trial to assess the safety of AZD6738 in combination with gemcitabine in&#xD;
      participants with advanced solid tumours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 1, non-randomised, multicentre, model-based dose escalation trial. This trial will&#xD;
      assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of&#xD;
      ascending doses of combined therapy with ATR inhibitor (AZD6738) and gemcitabine, in&#xD;
      participants with advanced solid tumours, followed by an expansion phase in participants with&#xD;
      advanced pancreatic ductal adenocarcinoma (PDAC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Continuous and intermittent administration schedule.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity for the combination of AZD6738 and gemcitabine.</measure>
    <time_frame>Through study completion</time_frame>
    <description>Number of participants with drug related toxicities reported during Cycle 1 (each cycle is 28 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate anti-tumour effect</measure>
    <time_frame>Through study completion for an average of 6 months</time_frame>
    <description>CT scan tumour measurement assessments from start of treatment until progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Continuous AZD6738 &amp; gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.&#xD;
Oral tablet AZD6738 once daily for 21 days of a 28 day cycle. Dose range from 40mg to 120mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent AZD6738 &amp; gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.&#xD;
Oral tablet AZD6738 once daily and intermittently for up to 12 days of a 28 day cycle. Dose range from 40mg to 120mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6738</intervention_name>
    <description>A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.</description>
    <arm_group_label>Continuous AZD6738 &amp; gemcitabine</arm_group_label>
    <arm_group_label>Intermittent AZD6738 &amp; gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Nucleoside metabolic inhibitor.</description>
    <arm_group_label>Continuous AZD6738 &amp; gemcitabine</arm_group_label>
    <arm_group_label>Intermittent AZD6738 &amp; gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent to participate.&#xD;
&#xD;
          -  Aged 18 years and over.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Dose escalation phase only: Patients with inoperable/unresectable, histologically&#xD;
             proven, locally advanced or metastatic solid tumour that has progressed on standard&#xD;
             therapy, or patients unwilling to receive standard therapy.&#xD;
&#xD;
          -  Treatment expansion phase only: Patients with inoperable, histologically proven,&#xD;
             locally advanced or metastatic pancreatic adenocarcinoma that has progressed on&#xD;
             conventional chemotherapy, or patients unwilling to receive standard therapy.&#xD;
&#xD;
          -  Documented evidence of progression (radiological or clinical) prior to trial entry.&#xD;
&#xD;
          -  Estimated life expectancy of ≥12 weeks.&#xD;
&#xD;
          -  Measurable tumour lesions that can be accurately assessed at baseline by computed&#xD;
             tomography (CT) and are suitable for repeated assessment as per RECIST 1.1 and&#xD;
             considered accessible for core biopsy.&#xD;
&#xD;
          -  Women of childbearing potential, male participants and their partners are required,&#xD;
             and must be willing, to use 2 highly effective forms of contraception for the duration&#xD;
             of the trial and for six (6) months after the completion of the trial treatment (see&#xD;
             section 11.13). Women of non-childbearing potential must meet one of the following:&#xD;
&#xD;
               -  Documented postmenopausal (defined as aged more than 50 years and amenorrhoeic&#xD;
                  for at least 12 months following cessation of all exogenous hormonal treatments).&#xD;
&#xD;
               -  Documentation of irreversible surgical sterilisation by hysterectomy, bilateral&#xD;
                  oophorectomy or bilateral salpingectomy with last menses &gt;1 year ago (excluding&#xD;
                  tubal ligation, radiation-induced oophorectomy).&#xD;
&#xD;
               -  Documented amenorrhoeic for 12 months (defined as women under the age of 50 years&#xD;
                  with serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and&#xD;
                  plasma oestradiol levels in the postmenopausal range for the institution).&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ataxia-telangiectasia syndrome.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Women of child-bearing potential and male participants who are unwilling to use 2&#xD;
             highly effective forms of contraception during the trial and for 6 months after the&#xD;
             completion of the trial treatment.&#xD;
&#xD;
          -  Cytotoxic chemotherapy within 21 days prior to start of trial treatment (greater than&#xD;
             5 half-lives is allowed for washout in patients treated with non-cytotoxic drugs).&#xD;
&#xD;
          -  Exposure to a small molecule IMP within 30 days or 5 half-lives (whichever is longer)&#xD;
             prior to the start of treatment.&#xD;
&#xD;
          -  Palliative radiotherapy within 21 days prior to start of trial treatment.&#xD;
&#xD;
          -  Immunotherapy within 42 days prior to start of trial treatment.&#xD;
&#xD;
          -  New treatment with bisphosphonates or denosumab for bone metastases within 5 days&#xD;
             prior to start of trial treatment (patients can receive a stable dose of&#xD;
             bisphosphonates or denosumab for bone metastases before and during the trial as long&#xD;
             as these were started at least 5 days prior to start of treatment).&#xD;
&#xD;
          -  Major surgery within 2 weeks prior to start of trial treatment (patients must have&#xD;
             recovered from any effects of major surgery).&#xD;
&#xD;
          -  Current treatment with steroids (doses of &gt;10mg of prednisone or equivalent) or other&#xD;
             immunosuppressive drugs within 14 days prior to start of trial treatment.&#xD;
&#xD;
          -  Any other malignancy which has been active or treated within the past three years&#xD;
             (with the exception of cervical intra-epithelial neoplasia, non-melanoma skin cancer,&#xD;
             ductal carcinoma in situ, stage 1 grade 1 endometrial carcinoma, or other solid&#xD;
             tumours curatively treated with no evidence of disease for ≥5 years prior).&#xD;
&#xD;
          -  Current treatments with known potent cytochrome P (CYP) 3A inhibitors, potent CYP3A&#xD;
             inducers, CYP3A4 and/or CYP2B6 substrates with a narrow therapeutic index or Pgp&#xD;
             modulators (wash out period of 5 half-lives, but three weeks for St. John's Wort, see&#xD;
             Appendix 4). The use of herbal supplements, homeopathic remedies or 'folk remedies' is&#xD;
             not permitted.&#xD;
&#xD;
          -  Impaired hepatic or renal function defined as:&#xD;
&#xD;
               -  AST or ALT &gt;2.5 x ULN (or 5 times if liver metastasis).&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 x ULN.&#xD;
&#xD;
               -  Glomerular filtration rate (GFR) (calculated by Cockcroft-Gault) of &lt;41 ml/min.&#xD;
&#xD;
          -  Inadequate bone marrow reserve or organ function defined as:&#xD;
&#xD;
               -  Absolute neutrophil count &lt;1.5 x 109/L.&#xD;
&#xD;
               -  Platelet count &lt;100 x 109/L with no blood transfusions in the past 28 days.&#xD;
&#xD;
               -  Haemoglobin &lt;90 g/L with no platelet transfusions in the past 28 days.&#xD;
&#xD;
          -  INR ≥1.25 above the normal range.&#xD;
&#xD;
          -  Haematuria +++.&#xD;
&#xD;
          -  Known history of cardiac dysfunction within the last 6 months defined as:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  NYHA Class II/III/IV heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Unstable cardiac arrhythmias not controlled with a pacemaker or medication (e.g.&#xD;
                  complete left bundle branch block or third degree heart block).&#xD;
&#xD;
          -  Any of the following cardiac criteria:&#xD;
&#xD;
               -  Mean resting corrected QT interval (QTc) &gt;470 msec for women, and &gt;450 msec for&#xD;
                  men obtained from 3 electrocardiograms (ECGs) 2-5 minutes apart using the&#xD;
                  Fridericia formula.&#xD;
&#xD;
               -  Patients with relative hypotension (&lt;90/60 mm Hg) or clinically relevant&#xD;
                  orthostatic hypotension, including a fall in blood pressure of &gt; 20 mmHg.&#xD;
&#xD;
               -  Patients at risk of brain perfusion problems (e.g. medical history of carotid&#xD;
                  stenosis, pre-syncope, syncope episodes or a history of transient ischaemic&#xD;
                  attack).&#xD;
&#xD;
               -  Uncontrolled hypertension (grade 2 or above) requiring clinical intervention.&#xD;
&#xD;
          -  Patients unable to swallow orally administered medication and with gastrointestinal&#xD;
             disorders likely to interfere with absorption of AZD6738.&#xD;
&#xD;
          -  Any other concurrent severe and/or uncontrolled medical condition that places the&#xD;
             patient at unacceptable risk of toxicity or non-compliance (examples include, but are&#xD;
             not limited to, active bleeding diatheses, renal transplant, uncontrolled major&#xD;
             seizure disorder, severe COPD, superior vena cava syndrome, extensive bilateral lung&#xD;
             disease on high resolution CT scan, severe Parkinson's disease, active inflammatory&#xD;
             bowel disease, psychiatric condition, or active infection (including any patient known&#xD;
             to have hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or requiring&#xD;
             systemic antibiotics, antifungals or antiviral drugs)). Screening for chronic&#xD;
             conditions is not required.&#xD;
&#xD;
          -  Prior exposure to an ATR inhibitor.&#xD;
&#xD;
          -  A known hypersensitivity to AZD6738 or gemcitabine (e.g. excessive myelosuppression),&#xD;
             any excipient of the products, or any contraindication to the combination of&#xD;
             anti-cancer agents.&#xD;
&#xD;
          -  Any unresolved toxicities from prior therapy of CTCAE grade &gt;1 (with the exception of&#xD;
             alopecia and CTCAE grade 2 neuropathy).&#xD;
&#xD;
          -  Spinal cord compression (unless asymptomatic, stable, and not requiring steroids for&#xD;
             at least 4 weeks prior to start of treatment).&#xD;
&#xD;
          -  Brain metastases (unless disease outside the central nervous system (CNS) is present,&#xD;
             no clinical evidence of progression since completion of CNS-directed therapy, at least&#xD;
             3 weeks between completion of radiotherapy and start of trial treatment, recovery from&#xD;
             significant (Grade ≥ 3) acute toxicity) with no on-going requirement for &gt;10 mg of&#xD;
             prednisone per day or an equivalent dose of other corticosteroid. If on&#xD;
             corticosteroids, the patient should be receiving a stable dose of corticosteroids&#xD;
             started at least 4 weeks prior to treatment).&#xD;
&#xD;
          -  Judgment by the Investigator that the patient should not participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duncan Jodrell</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRUK Cambridge Institute, University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Early Phase Team, Cambridge Clinical Trials Unit - Cancer Theme</last_name>
    <phone>01223216083</phone>
    <email>cctuep@addenbrookes.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cambridge Cancer Trials Centre, Coordination Team</last_name>
    <phone>01223216083</phone>
    <email>cctu.cancer@addenbrookes.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>CCTU- Cancer Theme</investigator_full_name>
    <investigator_title>Professor Duncan Jodrell</investigator_title>
  </responsible_party>
  <keyword>solid tumour</keyword>
  <keyword>locally advanced</keyword>
  <keyword>metastatic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

